291 related articles for article (PubMed ID: 26028416)
21. Use of administrative medical databases in population-based research.
Gavrielov-Yusim N; Friger M
J Epidemiol Community Health; 2014 Mar; 68(3):283-7. PubMed ID: 24248997
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data.
Sinnott SJ; Bennett K; Cahir C
Eur J Clin Pharmacol; 2017 Nov; 73(11):1449-1455. PubMed ID: 28819675
[TBL] [Abstract][Full Text] [Related]
23. Using secondary data sources for pharmacoepidemiology and outcomes research.
Harpe SE
Pharmacotherapy; 2009 Feb; 29(2):138-53. PubMed ID: 19170584
[TBL] [Abstract][Full Text] [Related]
24. Use of health care databases in pharmacoepidemiology.
Hennessy S
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
[TBL] [Abstract][Full Text] [Related]
25. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies.
Steinke D; Davey P
Clin Infect Dis; 2001 Sep; 33 Suppl 3():S193-205. PubMed ID: 11524719
[TBL] [Abstract][Full Text] [Related]
26. Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders.
Gilbertson DT; Bradbury BD; Wetmore JB; Weinhandl ED; Monda KL; Liu J; Brookhart MA; Gustafson SK; Roberts T; Collins AJ; Rothman KJ
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):269-77. PubMed ID: 26608680
[TBL] [Abstract][Full Text] [Related]
27. Efficient sampling approaches to address confounding in database studies.
Hanley JA; Dendukuri N
Stat Methods Med Res; 2009 Feb; 18(1):81-105. PubMed ID: 18815164
[TBL] [Abstract][Full Text] [Related]
28. Measured and accounted-for confounding in pharmacoepidemiologic studies: Some thoughts for practitioners.
Roy J; Mitra N
Pharmacoepidemiol Drug Saf; 2021 Mar; 30(3):277-282. PubMed ID: 33372303
[TBL] [Abstract][Full Text] [Related]
29. Clinical information for research; the use of general practice databases.
Lawrenson R; Williams T; Farmer R
J Public Health Med; 1999 Sep; 21(3):299-304. PubMed ID: 10528957
[TBL] [Abstract][Full Text] [Related]
30. Conditions for confounding of interactions.
Liu A; Abrahamowicz M; Siemiatycki J
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):287-96. PubMed ID: 26676843
[TBL] [Abstract][Full Text] [Related]
31. Interpretation of associations in pharmacoepidemiology.
Kaufman DW
Semin Hematol; 2008 Jul; 45(3):181-8. PubMed ID: 18582625
[TBL] [Abstract][Full Text] [Related]
32. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?
Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748
[TBL] [Abstract][Full Text] [Related]
33. Use of self-controlled designs in pharmacoepidemiology.
Hallas J; Pottegård A
J Intern Med; 2014 Jun; 275(6):581-9. PubMed ID: 24635348
[TBL] [Abstract][Full Text] [Related]
34. 'Why me?' versus 'why now?'--differences between operational hypotheses in case-control versus case-crossover studies.
Maclure M
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):850-3. PubMed ID: 17636552
[No Abstract] [Full Text] [Related]
35. High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting.
Rassen JA; Blin P; Kloss S; Neugebauer RS; Platt RW; Pottegård A; Schneeweiss S; Toh S
Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):93-106. PubMed ID: 36349471
[TBL] [Abstract][Full Text] [Related]
36. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
37. A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs.
Larsen MD; Cars T; Hallas J
Basic Clin Pharmacol Toxicol; 2013 Jan; 112(1):13-8. PubMed ID: 22901097
[TBL] [Abstract][Full Text] [Related]
38. Epidemiologic studies: pitfalls in interpretation.
Westhoff CL
Dialogues Contracept; 1995; 4(5):5-6, 8. PubMed ID: 12288680
[TBL] [Abstract][Full Text] [Related]
39. The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases.
Alarkawi D; Ali MS; Bliuc D; Center JR; Prieto-Alhambra D
JBMR Plus; 2018 Jul; 2(4):187-194. PubMed ID: 30283902
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacoepidemiological research with large health databases].
Andersohn F; Garbe E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Oct; 51(10):1135-44. PubMed ID: 18985407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
